Shirley Mei Ph.D.
Investigator – Regenerative Medicine Program, Ottawa Hospital Research Institute
Dr. Shirley Mei is an Investigator at the Ottawa Hospital Research Institute, who has more than 16 years of experience in the nonclinical development and translation of mesenchymal stem cell (MSC) therapy to clinic for critical illnesses that currently lack treatment. As a translational scientist, she has worked with ICU clinicians to conduct the worlds’ first-in-human clinical trial for septic shock patients with allogeneic MSC (NCT02421484). With a focus on bringing discoveries from the bench to the bedside, her current research includes studying how MSCs exert their immunomodulatory effect on immune cells, utilizing novel molecular strategies to enhance the benefit of cellular therapeutics, and developing scale-up/out strategies. Dr. Mei also serves as chief operating officer of Northern Therapeutics Inc., leading its nonclinical and manufacturing teams to test and develop enhanced cell therapy products. One of the successful product candidates is now being evaluated in a Phase 1 dose escalation study (AMETHYST trial NCT04961658). Dr. Mei received her MSc from the Department of Biochemistry & Biomedical Sciences at McMaster University, and a PhD from the Institute of Medical Science at the University of Toronto.
